The effectiveness of atorvastatin for the prevention of deep vein thrombosis in cancer patients undergoing chemotherapy

Table 3 Study safety end points

Efficacy end points	Atorvastatin N = 42	Rivaroxaban N = 44	p	OR;95% CI	p
Primary safety end points
Yes	2 (4.8%)	12 (27.3%)	0.007*	0.257; 0.070–0.940
No	40 (95.2%)	32 (72.7%)	0.007*	0.257; 0.070–0.940
Secondary safety end points
Yes	2 (4.8%)	6 (13.6%)	0.270*	0.320; 0.600–1.670	0,001^⁋
No	40 (95.2%)	38 (86.4%)	0.270*	0.320; 0.600–1.670	0,001^⁋
No Bleeding	38 (90,5%)	26 (59,1%)

ISSN: 1477-9560